Aquestive Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Aquestive Therapeutics

01/08/2025 12:20

Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The Warren New Jersey-based  company is expected to report a 43.7% decrease in revenue to $11.32 million from $20.1 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aquestive Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $8.00, about 52% above its last closing price of $3.84

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.17
-0.17
-0.24
Missed
-41.2
Dec. 31 2025
-0.13
-0.14
-0.19
Missed
-40
Sep. 30 2024
-0.12
-0.13
-0.13
Met
-2.6​
Jun. 30 2024
-0.13
-0.12
-0.03
Beat
75.8
​​Mar. 31 2024
-0.08
-0.08
-0.17
Missed
-106.5
Dec. 31 2023
-0.08
-0.08
-0.11
Missed
-37.5​
Sep. 30 2023
-0.11
-0.11
-0.03
Beat
73.5
Jun. 30 2023
-0.12
-0.12
-0.10
Beat
15.3

This summary was machine generated August 1 at 11:20 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)